Evidence map›Paper›PMID 40447766›Full record

Reviewnpj antimicrobials and resistance2025

Building microbial communities to improve antimicrobial strategies.

Laurence Couture, Fabrice Jean-Pierre, Jean-Philippe Côté

Abstract readReview
In one paragraph

Review in npj antimicrobials and resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laurence CoutureDépartement de biologie, Université de Sherbrooke, Sherbrooke, Québec, J1K 2R1, Canada.
Fabrice Jean-PierreDépartement de biologie, Université de Sherbrooke, Sherbrooke, Québec, J1K 2R1, Canada. fabrice.jean-pierre@usherbrooke.ca.
Jean-Philippe CôtéDépartement de biologie, Université de Sherbrooke, Sherbrooke, Québec, J1K 2R1, Canada. jp.cote@usherbrooke.ca.

Funding

CIHR 186304Cystic Fibrosis Foundation JEAN21F0Fonds de Recherche du Québec - Santé 295613Natural Sciences and Engineering Research Council of Canada RGPIN-06044
6 · The paper itself

Abstract

The lack of novel antimicrobial compounds in the development pipeline cries for innovative approaches regarding their discovery. In this Perspective, we discuss how microbial interactions play a significant role in shifting a pathogen's response to antibacterial treatment and negatively impact patient outcomes. Furthermore, we argue that interspecies interactions are often overlooked in treatment selection and current drug screening approaches, and modeling disease-relevant polymicrobial communities could help in unraveling novel strategies to eradicate pathogens.

Identifiers

PMID40447766
PMCPMC12125355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.